Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Amgen now has regulatory approval on both sides ... The European Commission has approved Lumykras (sotorasib) as a monotherapy for adults with advanced non-small-cell lung cancer (NSCLC) with ...

Amgen is facing a slowdown in uptake of its ... found that out of 20 patients treated with Lumakras (sotorasib) alongside chemotherapy with carboplatin and pemetrexed first-line, two-thirds ...

Sotorasib is the first-in-class OFF-state KRASG12C inhibitor ... A-CT reports personal fees from AMGEN, during the conduct of the study; personal fees and non-financial support from Novartis, personal ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...

After hours: 7:59:58 p.m. EST ...

After hours: 7:59:58 pm GMT-5 ...